Alligator Bioscience: First Patient Dosed With ATOR-1017 Developed for Metastasized Cancer
- Tuesday, December 17, 2019, 7:12
- Environment
- Add a comment
LUND, Sweden, Dec. 17, 2019 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized…
About the Author
adminasapcorp has written 42190 stories on this site.